• Alfuzosin HCl in BPH Research: Protocols, Innovations, and O

  2026-07-22

  Alfuzosin HCl, a functionally uroselective α1 adrenoceptor antagonist, enables reproducible lower urinary tract research with advanced gastroretentive delivery and robust in vitro workflow flexibility. This article translates the latest polymer-based formulation breakthroughs and spectroscopic quantification protocols into actionable guidance for benign prostatic hyperplasia (BPH) and urinary tract research teams.

• Demethyleneberberine: Translational Strategies for Next-Gen

  2026-07-22

  This thought-leadership article explores Demethyleneberberine’s multi-modal mechanisms, actionable protocol guidance, and competitive edge for translational researchers targeting inflammation, autoimmune hepatitis, neurodegeneration, and non-small cell lung cancer. Integrating mechanistic insight and scenario-driven advice, the piece advances beyond traditional product summaries, empowering research teams with evidence-based strategies and future-facing perspectives.

• YM 58483 (BTP2): Benchmark SOCE Inhibitor for Fibrosis Resea

  2026-07-21

  YM 58483 (BTP2) is a highly selective inhibitor of store-operated Ca2+ entry, validated for blocking CRAC and TRP channels central to immune and fibrotic signaling. Recent studies confirm its potency in suppressing T cell activation and postirradiation salivary gland fibrosis, positioning it as an essential tool for dissecting calcium-driven disease mechanisms.

• Shufeng Xingbi Therapy Modulates Immunity and Gut Flora in A

  2026-07-21

  The referenced study investigates Shufeng Xingbi Therapy (SFXBT) as a modulator of Th1/Th2 immune balance and intestinal microbiota in a rat model of allergic rhinitis. The findings suggest that SFXBT alleviates allergic inflammation via coordinated immunological and microbial mechanisms, offering experimental insights relevant to allergy and microbiome research.

• Anlotinib in Intra-Abdominal DSRCT: Case Insights and Resear

  2026-07-20

  This article examines the first documented use of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in treating intra-abdominal desmoplastic small round cell tumor (IADSRCT). The case report demonstrates significant tumor reduction and manageable toxicity, offering new directions for research and clinical management of this rare malignancy.

• Salvianolic Acid B Inhibits LH2 to Attenuate Pulmonary Fibro

  2026-07-20

  The reference study demonstrates that Salvianolic acid B (Dan Shen Suan B) directly inhibits lysyl hydroxylase 2 (LH2), a collagen-modifying enzyme central to pulmonary fibrosis progression. This mechanistic insight positions Salvianolic acid B as a promising antifibrotic compound for targeting extracellular matrix remodeling in fibrotic lung disease.

• Hexose Diphosphate: Advancing Energy Homeostasis Research

  2026-07-19

  Hexose diphosphate serves as a pivotal tool in dissecting metabolic flux, inflammation regulation, and tissue injury responses. Its water solubility and precise role in central carbon metabolism make it indispensable for cardiovascular, aging, and inflammatory signaling models.

• Hexose Diphosphate in Energy Homeostasis and Inflammation Mo

  2026-07-18

  Hexose diphosphate empowers metabolic and inflammation research by enabling precise control over glycolytic flux and signaling modulation. Discover optimized protocols, advanced applications, and troubleshooting strategies to maximize reproducibility and insight in cardiovascular and aging models.

• FLAG tag Peptide: Precision Tagging for Recombinant Protein

  2026-07-17

  The FLAG tag Peptide (DYKDDDDK) from APExBIO empowers researchers to streamline recombinant protein detection and purification with high specificity and gentle elution. This article translates bench protocols, troubleshooting, and advanced workflows into actionable insights, leveraging new findings in oligodendrocyte biology to illustrate real-world impact.

• S Tag Peptide: Technical Guide for Protein Detection and Pur

  2026-07-17

  S Tag Peptide (SKU A6007) addresses challenges in recombinant protein detection, purification, and solubility enhancement by serving as a highly soluble, 15-amino acid fusion tag. It is well suited for workflows requiring antibody-based detection or affinity purification, but not for applications needing direct enzymatic activity or ethanol solubilization.

• BMX-IN-1: Selective BMX Kinase Inhibitor for Infection & Can

  2026-07-16

  BMX-IN-1 unlocks targeted inhibition of BMX kinase, bridging cancer and infectious disease research with high specificity and potency. This protocol-centric guide translates recent breakthroughs in host-pathogen interactions into actionable workflows and troubleshooting strategies for advanced cell signaling studies.

• PPARγ Activation Modulates Macrophage Polarization in IBD Mo

  2026-07-16

  This study demonstrates that activating PPARγ, including via pioglitazone treatment, shifts macrophage polarization from proinflammatory M1 to anti-inflammatory M2 phenotypes in dextran sulfate sodium-induced murine colitis. The findings reveal that modulation of the STAT-1/STAT-6 signaling axis underlies both the immunological and clinical improvements observed, providing mechanistic insight for inflammation-targeted metabolic research.

• Golgi-Tracker Green: Advanced Live-Cell Golgi Apparatus Imag

  2026-07-15

  Golgi-Tracker Green, a BODIPY FL-labeled C5-ceramide probe, delivers high specificity and photostability for live-cell Golgi apparatus labeling, surpassing conventional probes. This article guides researchers through optimized protocols, troubleshooting, and experimental use-cases, especially for dynamic studies of lipid transport and sphingolipid metabolism in disease contexts.

• Birinapant (TL32711): Advancing Apoptosis Targeting in Cance

  2026-07-15

  Explore how Birinapant (TL32711) is transforming apoptosis research in cancer biology by bridging mechanistic insight with translational strategy. This article contextualizes Birinapant’s unique IAP antagonism within emerging biomarker-driven paradigms—highlighting MDM1/p53 modulation, protocol nuances, and forward-looking translational opportunities for researchers seeking to overcome therapy resistance.

• Anlotinib Hydrochloride: Multi-Target Angiogenesis Inhibitio

  2026-07-14

  The reference study establishes anlotinib hydrochloride as a highly effective multi-target tyrosine kinase inhibitor, directly suppressing VEGFR2, PDGFRβ, and FGFR1 to inhibit angiogenesis in vitro and in vivo. These findings demonstrate superior anti-angiogenic efficacy compared to established TKIs, with direct implications for tumor biology and cancer therapy.

459 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page